Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-06-21

AUTHORS

Sergio Schwartzman, Roy Fleischmann, G James Morgan

ABSTRACT

Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy. More... »

PAGES

s3-s11

References to SciGraph publications

  • 2002-03-27. How does infliximab work in rheumatoid arthritis? in ARTHRITIS RESEARCH & THERAPY
  • 2002-05-09. Epidemiology and genetics of rheumatoid arthritis in ARTHRITIS RESEARCH & THERAPY
  • 1994-12. The Costs of Rheumatoid Arthritis in PHARMACOECONOMICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/ar1013

    DOI

    http://dx.doi.org/10.1186/ar1013

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1051489549

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15228615


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arthritis, Rheumatoid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Necrosis Factor-alpha", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Hospital for Special Surgery, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239915.5", 
              "name": [
                "Hospital for Special Surgery, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schwartzman", 
            "givenName": "Sergio", 
            "id": "sg:person.014133305773.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Texas Southwestern Medical Center, Dallas, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.267313.2", 
              "name": [
                "University of Texas Southwestern Medical Center, Dallas, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fleischmann", 
            "givenName": "Roy", 
            "id": "sg:person.01065106031.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA", 
              "id": "http://www.grid.ac/institutes/grid.413480.a", 
              "name": [
                "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Morgan", 
            "givenName": "G James", 
            "id": "sg:person.016267004752.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/ar578", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050495934", 
              "https://doi.org/10.1186/ar578"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00019053-199406060-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020626855", 
              "https://doi.org/10.2165/00019053-199406060-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar549", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004017405", 
              "https://doi.org/10.1186/ar549"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-06-21", 
        "datePublishedReg": "2004-06-21", 
        "description": "Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/ar1013", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1297499", 
            "issn": [
              "1478-6354", 
              "1478-6362"
            ], 
            "name": "Arthritis Research & Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "Suppl 2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "6"
          }
        ], 
        "keywords": [
          "disease-modifying anti-rheumatic drugs", 
          "symptoms of RA", 
          "joint-space narrowing", 
          "rheumatoid arthritis", 
          "physical function", 
          "score progression", 
          "joint erosions", 
          "first-line therapy", 
          "anti-TNF agents", 
          "anti-rheumatic drugs", 
          "early rheumatoid arthritis", 
          "necrosis factor antagonists", 
          "quality of life", 
          "joint destruction", 
          "psoriatic arthritis", 
          "TNF antagonists", 
          "clinical trials", 
          "factor antagonists", 
          "incomplete response", 
          "equal efficacy", 
          "pharmacodynamic properties", 
          "etanercept", 
          "comparative efficacy", 
          "biologic effects", 
          "infliximab", 
          "adalimumab", 
          "arthritis", 
          "patients", 
          "monoclonal antibodies", 
          "specific agents", 
          "methotrexate", 
          "therapy", 
          "symptoms", 
          "progression", 
          "antagonist", 
          "signs", 
          "efficacy", 
          "agents", 
          "narrowing", 
          "rheumatologists", 
          "TNF", 
          "trials", 
          "antibodies", 
          "evidence", 
          "drugs", 
          "outcomes", 
          "direct comparison", 
          "function", 
          "years", 
          "response", 
          "combination", 
          "destruction", 
          "life", 
          "protein", 
          "rate", 
          "effect", 
          "experience", 
          "use", 
          "differs", 
          "soluble proteins", 
          "quality", 
          "comparison", 
          "erosion", 
          "USA", 
          "decisions", 
          "properties", 
          "decrease total joint score progression", 
          "total joint score progression", 
          "joint score progression"
        ], 
        "name": "Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?", 
        "pagination": "s3-s11", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1051489549"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/ar1013"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15228615"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/ar1013", 
          "https://app.dimensions.ai/details/publication/pub.1051489549"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:16", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_391.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/ar1013"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/ar1013'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/ar1013'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/ar1013'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/ar1013'


     

    This table displays all metadata directly associated to this object as RDF triples.

    187 TRIPLES      22 PREDICATES      104 URIs      93 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/ar1013 schema:about N20b898ec9c764eaf8d020559d37ac48d
    2 N2cedcf90946a4aaeb328f9aced120f99
    3 N3b9c1ff6a69446c3aca59801f19b590c
    4 N7a55d5fae3c04a3782b5b29af93166d1
    5 N87ea533d535d4725b980135bd9f29e67
    6 Na84474645fc946ffaeeb286cccf02d2e
    7 anzsrc-for:11
    8 anzsrc-for:1103
    9 schema:author N7b62c1982b91466d8f645381a59c181f
    10 schema:citation sg:pub.10.1186/ar549
    11 sg:pub.10.1186/ar578
    12 sg:pub.10.2165/00019053-199406060-00005
    13 schema:datePublished 2004-06-21
    14 schema:datePublishedReg 2004-06-21
    15 schema:description Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA--infliximab, etanercept, and adalimumab--have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties of each differs significantly from those of the others. All three agents are effective and safe, and can improve the quality of life in patients with RA. Although no direct comparisons are available, clinical trials provide evidence that can be used to evaluate the comparative efficacy of these agents. Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve physical function. Etanercept is approved with and without methotrexate for patients who have demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in combination with methotrexate, and might improve physical function. When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy.
    16 schema:genre article
    17 schema:inLanguage en
    18 schema:isAccessibleForFree true
    19 schema:isPartOf N74da8dc1953a4a4ba37d1091eb22bfc5
    20 Nffd53c642cc94648a341f7ee4cd6d1de
    21 sg:journal.1297499
    22 schema:keywords TNF
    23 TNF antagonists
    24 USA
    25 adalimumab
    26 agents
    27 antagonist
    28 anti-TNF agents
    29 anti-rheumatic drugs
    30 antibodies
    31 arthritis
    32 biologic effects
    33 clinical trials
    34 combination
    35 comparative efficacy
    36 comparison
    37 decisions
    38 decrease total joint score progression
    39 destruction
    40 differs
    41 direct comparison
    42 disease-modifying anti-rheumatic drugs
    43 drugs
    44 early rheumatoid arthritis
    45 effect
    46 efficacy
    47 equal efficacy
    48 erosion
    49 etanercept
    50 evidence
    51 experience
    52 factor antagonists
    53 first-line therapy
    54 function
    55 incomplete response
    56 infliximab
    57 joint destruction
    58 joint erosions
    59 joint score progression
    60 joint-space narrowing
    61 life
    62 methotrexate
    63 monoclonal antibodies
    64 narrowing
    65 necrosis factor antagonists
    66 outcomes
    67 patients
    68 pharmacodynamic properties
    69 physical function
    70 progression
    71 properties
    72 protein
    73 psoriatic arthritis
    74 quality
    75 quality of life
    76 rate
    77 response
    78 rheumatoid arthritis
    79 rheumatologists
    80 score progression
    81 signs
    82 soluble proteins
    83 specific agents
    84 symptoms
    85 symptoms of RA
    86 therapy
    87 total joint score progression
    88 trials
    89 use
    90 years
    91 schema:name Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    92 schema:pagination s3-s11
    93 schema:productId N653e16f40f8847e486aad5a465d9dc0b
    94 N895438f2d3514cfcb2af80d5bdfd0543
    95 Na7819894271540d2ba9355d370901471
    96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051489549
    97 https://doi.org/10.1186/ar1013
    98 schema:sdDatePublished 2021-12-01T19:16
    99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    100 schema:sdPublisher N18d784e3622244268a0c5ff0a18a0d12
    101 schema:url https://doi.org/10.1186/ar1013
    102 sgo:license sg:explorer/license/
    103 sgo:sdDataset articles
    104 rdf:type schema:ScholarlyArticle
    105 N18d784e3622244268a0c5ff0a18a0d12 schema:name Springer Nature - SN SciGraph project
    106 rdf:type schema:Organization
    107 N1efeff5bb2194e579482d8db6e922f33 rdf:first sg:person.01065106031.43
    108 rdf:rest Na056b9f76e4446be86305e5e209651f0
    109 N20b898ec9c764eaf8d020559d37ac48d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    110 schema:name Humans
    111 rdf:type schema:DefinedTerm
    112 N2cedcf90946a4aaeb328f9aced120f99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Treatment Outcome
    114 rdf:type schema:DefinedTerm
    115 N3b9c1ff6a69446c3aca59801f19b590c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Animals
    117 rdf:type schema:DefinedTerm
    118 N653e16f40f8847e486aad5a465d9dc0b schema:name doi
    119 schema:value 10.1186/ar1013
    120 rdf:type schema:PropertyValue
    121 N74da8dc1953a4a4ba37d1091eb22bfc5 schema:issueNumber Suppl 2
    122 rdf:type schema:PublicationIssue
    123 N7a55d5fae3c04a3782b5b29af93166d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Tumor Necrosis Factor-alpha
    125 rdf:type schema:DefinedTerm
    126 N7b62c1982b91466d8f645381a59c181f rdf:first sg:person.014133305773.18
    127 rdf:rest N1efeff5bb2194e579482d8db6e922f33
    128 N87ea533d535d4725b980135bd9f29e67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Arthritis, Rheumatoid
    130 rdf:type schema:DefinedTerm
    131 N895438f2d3514cfcb2af80d5bdfd0543 schema:name pubmed_id
    132 schema:value 15228615
    133 rdf:type schema:PropertyValue
    134 Na056b9f76e4446be86305e5e209651f0 rdf:first sg:person.016267004752.30
    135 rdf:rest rdf:nil
    136 Na7819894271540d2ba9355d370901471 schema:name dimensions_id
    137 schema:value pub.1051489549
    138 rdf:type schema:PropertyValue
    139 Na84474645fc946ffaeeb286cccf02d2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Antibodies, Monoclonal
    141 rdf:type schema:DefinedTerm
    142 Nffd53c642cc94648a341f7ee4cd6d1de schema:volumeNumber 6
    143 rdf:type schema:PublicationVolume
    144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    145 schema:name Medical and Health Sciences
    146 rdf:type schema:DefinedTerm
    147 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    148 schema:name Clinical Sciences
    149 rdf:type schema:DefinedTerm
    150 sg:journal.1297499 schema:issn 1478-6354
    151 1478-6362
    152 schema:name Arthritis Research & Therapy
    153 schema:publisher Springer Nature
    154 rdf:type schema:Periodical
    155 sg:person.01065106031.43 schema:affiliation grid-institutes:grid.267313.2
    156 schema:familyName Fleischmann
    157 schema:givenName Roy
    158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43
    159 rdf:type schema:Person
    160 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
    161 schema:familyName Schwartzman
    162 schema:givenName Sergio
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
    164 rdf:type schema:Person
    165 sg:person.016267004752.30 schema:affiliation grid-institutes:grid.413480.a
    166 schema:familyName Morgan
    167 schema:givenName G James
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30
    169 rdf:type schema:Person
    170 sg:pub.10.1186/ar549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004017405
    171 https://doi.org/10.1186/ar549
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1186/ar578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050495934
    174 https://doi.org/10.1186/ar578
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.2165/00019053-199406060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020626855
    177 https://doi.org/10.2165/00019053-199406060-00005
    178 rdf:type schema:CreativeWork
    179 grid-institutes:grid.239915.5 schema:alternateName Hospital for Special Surgery, New York, NY, USA
    180 schema:name Hospital for Special Surgery, New York, NY, USA
    181 rdf:type schema:Organization
    182 grid-institutes:grid.267313.2 schema:alternateName University of Texas Southwestern Medical Center, Dallas, TX, USA
    183 schema:name University of Texas Southwestern Medical Center, Dallas, TX, USA
    184 rdf:type schema:Organization
    185 grid-institutes:grid.413480.a schema:alternateName Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
    186 schema:name Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
    187 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...